Nathan Weinstein
Stock Analyst at Aegis Capital
(0.26)
# 4,381
Out of 5,090 analysts
61
Total ratings
13.33%
Success rate
-26.26%
Average return
Main Sectors:
Stocks Rated by Nathan Weinstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVGN Evogene | Maintains: Buy | $100 → $80 | $1.11 | +7,107.21% | 2 | Sep 12, 2022 | |
| DRIO DarioHealth | Maintains: Buy | $400 → $300 | $11.84 | +2,433.78% | 6 | Aug 18, 2022 | |
| VNRX VolitionRx | Maintains: Buy | $9 → $6 | $0.30 | +1,902.00% | 5 | Aug 15, 2022 | |
| IMUX Immunic | Maintains: Buy | $40 → $35 | $0.66 | +5,166.33% | 2 | Aug 8, 2022 | |
| STXS Stereotaxis | Initiates: Buy | $6 | $2.41 | +148.96% | 1 | Jul 12, 2022 | |
| ORMP Oramed Pharmaceuticals | Maintains: Buy | $35 → $30 | $2.69 | +1,015.24% | 5 | May 16, 2022 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $10 | $13.47 | -25.76% | 1 | Mar 29, 2022 | |
| MDWD MediWound | Maintains: Buy | $63 → $49 | $17.68 | +177.15% | 4 | Mar 21, 2022 | |
| ENVB Enveric Biosciences | Downgrades: Hold | $63,000 → $1,800 | $6.79 | +26,409.57% | 2 | Mar 8, 2022 | |
| CING Cingulate | Initiates: Buy | $2,160 | $3.99 | +54,035.34% | 1 | Jan 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $120 | $2.48 | +4,738.71% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $1.11 | +800.90% | 2 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $160 | $220.36 | -27.39% | 2 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $29.91 | +87.23% | 2 | Sep 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $27 | $4.32 | +525.00% | 3 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $0.66 | +5,238.62% | 4 | Jun 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.15 | +458.14% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $8.94 | +738.93% | 1 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $88 | $2.34 | +3,660.68% | 3 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $180 | $4.33 | +4,057.04% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $135 | $4.29 | +3,046.85% | 3 | Aug 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $5.64 | +148.23% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $220 | $16.54 | +1,230.11% | 7 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8.5 | $4.79 | +77.45% | 1 | Mar 23, 2020 |
Evogene
Sep 12, 2022
Maintains: Buy
Price Target: $100 → $80
Current: $1.11
Upside: +7,107.21%
DarioHealth
Aug 18, 2022
Maintains: Buy
Price Target: $400 → $300
Current: $11.84
Upside: +2,433.78%
VolitionRx
Aug 15, 2022
Maintains: Buy
Price Target: $9 → $6
Current: $0.30
Upside: +1,902.00%
Immunic
Aug 8, 2022
Maintains: Buy
Price Target: $40 → $35
Current: $0.66
Upside: +5,166.33%
Stereotaxis
Jul 12, 2022
Initiates: Buy
Price Target: $6
Current: $2.41
Upside: +148.96%
Oramed Pharmaceuticals
May 16, 2022
Maintains: Buy
Price Target: $35 → $30
Current: $2.69
Upside: +1,015.24%
Trevi Therapeutics
Mar 29, 2022
Initiates: Buy
Price Target: $10
Current: $13.47
Upside: -25.76%
MediWound
Mar 21, 2022
Maintains: Buy
Price Target: $63 → $49
Current: $17.68
Upside: +177.15%
Enveric Biosciences
Mar 8, 2022
Downgrades: Hold
Price Target: $63,000 → $1,800
Current: $6.79
Upside: +26,409.57%
Cingulate
Jan 11, 2022
Initiates: Buy
Price Target: $2,160
Current: $3.99
Upside: +54,035.34%
Dec 7, 2021
Initiates: Buy
Price Target: $120
Current: $2.48
Upside: +4,738.71%
Nov 1, 2021
Maintains: Buy
Price Target: $9 → $10
Current: $1.11
Upside: +800.90%
Sep 22, 2021
Maintains: Buy
Price Target: $180 → $160
Current: $220.36
Upside: -27.39%
Sep 9, 2021
Maintains: Buy
Price Target: $60 → $56
Current: $29.91
Upside: +87.23%
Aug 17, 2021
Maintains: Buy
Price Target: $26 → $27
Current: $4.32
Upside: +525.00%
Jun 7, 2021
Maintains: Buy
Price Target: $40 → $35
Current: $0.66
Upside: +5,238.62%
Mar 22, 2021
Initiates: Buy
Price Target: $12
Current: $2.15
Upside: +458.14%
Jan 26, 2021
Initiates: Buy
Price Target: $75
Current: $8.94
Upside: +738.93%
Oct 19, 2020
Maintains: Buy
Price Target: $104 → $88
Current: $2.34
Upside: +3,660.68%
Oct 8, 2020
Initiates: Buy
Price Target: $180
Current: $4.33
Upside: +4,057.04%
Aug 3, 2020
Maintains: Buy
Price Target: $195 → $135
Current: $4.29
Upside: +3,046.85%
Jul 13, 2020
Initiates: Buy
Price Target: $14
Current: $5.64
Upside: +148.23%
May 4, 2020
Maintains: Buy
Price Target: $180 → $220
Current: $16.54
Upside: +1,230.11%
Mar 23, 2020
Initiates: Buy
Price Target: $8.5
Current: $4.79
Upside: +77.45%